Hyperbaric Oxygen Compared to Pharmaceutical Therapies for Fibromyalgia Syndrome
Status:
Unknown status
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
The investigators have previously studied the efficacy of hyperbaric oxygen therapy (HBOT) as
a treatment for Fibromyalgia syndrome (FMS) in a prospective, active control, crossover
clinical trial. The results demonstrated significant amelioration of all FMS symptoms, with
significant improvement in life quality; furthermore, the investigators were able to
demonstrate significant neuroplasticity on SPECT imaging, with a decrease of the
hyperactivity in posterior regions and elevation of the reduced activity in frontal areas.
In the proposed study, the investigators intend to both repeat and expand our previous
findings, treating FMS patients with HBOT while performing an extensive of evaluation both
before and after treatment.
In the current study, the investigators plan to compare HBOT to current standard of care of
FMS (pharmacological and non - pharmacological).